Xeris Biopharma Holdings Capital Expenditures (CapEx) Growth & History (XERS)
Xeris Biopharma Holdings's capital expenditures (capex) was $696,000 for fiscal 2025.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $696,000 | −$172,000 | −19.82% |
| 2024 | 2024-12-31 | $868,000 | −$1.4M | −61.64% |
| 2023 | 2023-12-31 | $2.3M | $1.7M | +331.87% |
| 2022 | 2022-12-31 | $524,000 | −$561,000 | −51.71% |
| 2021 | 2021-12-31 | $1.1M | $708,000 | +187.80% |
| 2020 | 2020-12-31 | $377,000 | — | — |
Xeris Biopharma Holdings quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $209,000 | −$70,000 | −25.09% |
| Q1 2026 | 2026-03-31 | $325,000 | — | — |
| Q4 2025 | 2025-12-31 | $333,000 | — | — |
| Q3 2025 | 2025-09-30 | $71,000 | — | — |
| Q2 2025 | 2025-06-30 | $279,000 | — | — |
Xeris Biopharma Holdings capital expenditures (capex) trends
Over the last five fiscal years, Xeris Biopharma Holdings's capital expenditures (capex) increased from $377,000 to $696,000, a change of $319,000. The latest reported quarter, Q2 2026, shows $209,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xeris Biopharma Holdings source filings ↗